20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T12345 | CBP/p300-IN-3 | P300/CBP-IN-3 | Histone Acetyltransferase |
CBP/p300-IN-3 (P300/CBP-IN-3) is an inhibitor of p300/CBP histone acetyltransferase. | |||
T39826 | CBP/p300-IN-8 | CBP/p300-IN-8 | |
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains . CBP/p300-IN-8 inhibits CBP ( IC 50 =0.01-0.1 μΜ) and BRD4 ( IC 50 =1-1000 μΜ) activity. | |||
T40344 | CBP/p300-IN-14 | CBP/p300-IN-14 | |
CBP/p300-IN-14, efficiently inhibits CBP/EP300 (lysine acetyltransferase) with an IC50 value of 3.3 nM. | |||
T40144 | CBP/p300 ligand 2 | ||
CBP/p300 ligand 2 is a selective ligand that binds to the target protein for PROTAC of dCBP-1, a potent and selective heterobifunctional degrader of p300/CBP. | |||
T40143 | PROTAC CBP/P300 Degrader-1 | PROTAC CBP/P300 Degrader-1 | |
PROTAC CBP/P300 Degrader-1 is an effective compound that degrades CBP/P300 in a potent manner. It significantly reduces cell viability in various cancer cell lines. | |||
T40142 | Thalidomide-NH-CBP/p300 ligand 2 | Thalidomide-NH-CBP/p300 ligand 2 | |
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440). | |||
T12346 | CBP/p300-IN-5 | P300/CBP-IN-5 | Epigenetic Reader Domain |
P300/CBP-IN-5 is a potent inhibitor of p300/CBP histone acetyltransferase (IC50 of 18.8 nM). | |||
T10702 | CBP/p300-IN-2 | CBP/EP300-IN-2 | Epigenetic Reader Domain , c-Myc |
CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc). | |||
T9370 | DCBP-1 | Epigenetic Reader Domain , Ligand for E3 Ligase | |
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing. | |||
T8778 | TTK21 | Epigenetic Reader Domain | |
TTK21 is an activator of CBP/p300 histone acetyltransferase activity. | |||
T63122 | CBP/p300-IN-19 | ||
CBP/p300-IN-19 is a potent inhibitor of p300/CBP HAT, which can act on P300-HAT (IC50: 1.4 μM), CBP-HAT (IC50: 1.4 μm), 2.2 μM), PCAF (IC50>100 μM), and Myst3 (IC50>100 μM). CBP/p300-IN-19 has anti-tumor activity. | |||
T63110 | CBP/p300-IN-15 | ||
CBP/p300-IN-15 (compound 13a) is a potent inhibitor of p300 (IC50: 2.5 nM) and CBP (IC50: 28.0 nM). p300-IN-15 inhibits OVCAR-3 cells (EC50: 0.865 μM) and A2780 cells (EC50. 2.71 μM). 2.71 μM). CBP/p300-IN-15 can be used... | |||
T62720 | CBP/p300-IN-18 | ||
CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM). | |||
T62415 | CBP/p300-IN-17 | ||
CBP/p300-IN-17 (compound 7) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.18 μM) and LK2 H3K27 (IC50: 0.69 μM). | |||
T79395 | CBP/p300-IN-21 | Epigenetic Reader Domain | |
CBP/p300-IN-21 (Compound 5d), a selective inhibitor of CBP/p300 with IC50 values of 0.07 μM for p300 and 1.755 μM for CBP, reduces H3K18Ac levels and inhibits the growth of 4T1 tumors in mice [1]. | |||
T62700 | CBP/p300-IN-16 | ||
CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM). | |||
T72815 | CBP/p300-IN-10 | ||
CBP/p300-IN-10, a potent inhibitor targeting histone acetyltransferase enzymes EP300 and CREBBP, exhibits IC50 values of 26 nM and 39 nM, respectively. This compound shows potential for anticancer research applications. | |||
T3635 | IQ 1 | IQ1,IQ-1 | Wnt/beta-catenin |
IQ 1 has multiple roles, such as maintaining the multifunctionality of mouse ESCs, decreasing Wnt-stimulated phosphorylation, blocking PP2A/Nkd interactions, and so on. | |||
T63565 | CBP/p300-IN-19 hydrochloride | ||
CBP/p300-IN-19 hydrochloride is a selective and potent inhibitor of p300/CBP HAT, capable of acting on p300-HAT (IC50: 1.4 μM), CBP-HAT (IC50: 2.2 μM), PCAF (IC50>100 μM), Myst3 (IC50>100 μM). CBP/p300-IN-19 hydrochlorid... | |||
T8658 | NEO2734 | EP31670 | Epigenetic Reader Domain , Histone Acetyltransferase |
NEO2734 (EP31670) is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains). |